Market Opportunity

Urinary Tract Infections

$8 billion

~ 1 in 2 Women &

Most Common

Hospital Acquired Infection [5]

Bladder Cancer

$2 billion

> 81K New Cases in US 2018 [3]

tttttt.png

Bladder Overactivity

$4 billion

> 10% of Adults

Increases with Age [2]

Pain & Inflammation

$4 billion

~ 3 to 8 million Women in US [4]

UroPharma is uniquely positioned to bring a number of direct-to-bladder treatments to people with bladder diseases and disorders, notably common in neurological conditions, e.g. multiple sclerosis (MS) and spinal cord injuries (SCI). Such treatment opportunities also include people who suffer urinary tract infections (UTI), bladder cancer, overactive bladder (OAB) and pain & inflammation.

UroPharma can roll out drug-delivery combinations into each of the 4 target markets shown in the graphic. Due to the aging of populations, these target markets are expected to continue to increase substantially year on year.